Drug Target Review – Publications

Issue #2 2020

The next issue of Drug Target Review goes to press on 21 May 2020 and will feature:

• In-Depth Focuses on: Screening, Stem Cells and Imaging
• A focus on the latest advances in genomics and antibodies
• The latest trends in mass spectrometry
• And much more…

To receive our latest journal, you can secure your free print and/or digital copy here.

Latest issue

Issue #1 2020

Drug Target Review – Issue 1 2020

This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve…

By Drug Target Review

Issue #1 2020

Assays In-Depth Focus 2020

Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic…

By Drug Target Review

Issue #1 2020

Antibodies In-Depth Focus 2020

This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an…

By Drug Target Review

Issue #1 2020

Informatics In-Depth Focus 2020

The articles in this in-depth focus explain how informatics aids in the development of genomic research and outline the next…

By Drug Target Review

Issue #1 2020

Lab Automation In-Depth Focus 2020

In this in-depth focus are features on the best data management options currently available and how the future of drug…

By Drug Target Review

Issue #1 2020

Expert view: The path to the high-hanging fruit: access to…

Therapeutic monoclonal antibodies are proven and effective treatment options but many of the ‘low-hanging fruit’ therapeutics have already been identified.

By Berkeley Lights

Issue #1 2020

TCR therapy – an attractive alternative to CAR T

Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However,…

By Nikki Withers (Drug Target Review)

Issue #1 2020

Pooling research and development resources to tackle emerging threats

Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.

By Sheraz Gul (Fraunhofer Institute for Molecular Biology and Applied Ecology)

Issue #1 2020

Expert view: Targeting the cGAS-STING pathway with a new Transcreener…

DNA in the cytoplasm is an indicator of microbial infection, serving as a danger signal and resulting in induction of…

By BellBrook Labs

Issue #1 2020

Expert view: Are you ready for next generation therapeutic antibodies?

Do not let the challenges of selecting and analysing bispecific antibodies create havoc in your antibody development.

By ForteBio

Issue #1 2020

In vitro platforms for de-risking nephrotoxicity during drug development

If not correctly assessed, drug candidates with undesirable safety issues may progress through clinical development, resulting in costly failures later…

By Colin Brown (Newcells Biotech), Sandy Primrose (Newcells Biotech)

Issue #1 2020

Genomic assays: on the brink of revolutionising human healthcare

Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients…

By Dr Pushpanathan Muthuirulan (Harvard University)

Issue #1 2020

Expert view: How automation can improve cell stability and productivity…

During cell line development, key attributes such as cell productivity, stability and monoclonality are required before progressing cells for manufacturing.

By Sphere Fluidics Ltd.

Issue #1 2020

Expert view: Early product characterisation mitigates risks in biologics development

Developers of small molecule pharmaceuticals perform a battery of analytical tests before early clinical trials.

By MilliporeSigma

Issue #1 2020

Scientific data management: the core of quality

Gone are the days where mere data is considered king. We now understand the real value is in proper data…

By Roberto Castelnovo (NL42 Consulting)

Issue #1 2020

Cell line development for therapeutic proteins – current perspectives and…

Development of cell line expression systems to produce biologic medicines is complex, multi-stage and time consuming, requiring specific expertise and…

By Dr Jonathan H Dempsey (Dempsey Consulting)

Issue #1 2020

Application note: A rapid method to quantitatively screen bispecific antibodies…

Scientists at Celgene Corporation developed a screening process incorporating the Octet® HTX system to identify pools and clones with higher…

By ForteBio

Issue #1 2020

Laboratory automation in early drug discovery

The future of drug discovery lies in an automated world where the workflows for biological assays, chemical synthesis and data…

By Darren Plant (AstraZeneca), Dr David Murray (AstraZeneca), Dr Mark Wigglesworth (AstraZeneca), Geoff Holdgate (AstraZeneca), Helen Plant (AstraZeneca), John Vincent (AstraZeneca), Paul Harper (AstraZeneca)

Issue #1 2020

Petabytes of data – how informatics is transforming precision medicine

Advances in informatics have afforded researchers the ability to extrapolate petabytes of human genomics data and translate it into biologically…

By Nikki Withers (Drug Target Review)

Issue #1 2020

Not everyone loves surprises: know your ADC’s critical quality attributes

The importance of product characterisation throughout the entire drug development process cannot be understated. Success, money and lives depend on…

By Martin De Cecco (Merck), Omar Lamm (MilliporeSigma)

Issue #1 2020

The race to find a coronavirus treatment: are antibodies the…

At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and…

By Nikki Withers (Drug Target Review)

Issue #1 2020

Antibodies allow for a targeted approach to cancer therapy

Cancer can be an immovable beast, tenacious in its numerous mechanisms to thrive and grow. However, the healthcare industry has…

By Nikki Withers (Drug Target Review)

Issue #1 2020

How labs become AI ready with advanced informatics infrastructures

To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their…

By Unjulie Bhanot (IDBS)

Past Issues

Issue #4 2019

Drug Target Review – Issue 4 2019

Issue #3 2019

Drug Target Review – Issue 3 2019

Issue #2 2019

Drug Target Review – Issue 2 2019

Issue #1 2019

Drug Target Review – Issue 1 2019

Issue #4 2018

Drug Target Review – Issue 4 2018

Issue #3 2018

Drug Target Review – Issue 3 2018

Issue #2 2018

Drug Target Review – Issue #2 2018

Issue #1 2018

Drug Target Review – Issue #1 2018

Issue #4 2017

Drug Target Review – Issue #4 2017

Issue #3 2017

Drug Target Review – Issue #3 2017

Issue #2 2017

Drug Target Review – Issue #2 2017

Issue #1 2017

Drug Target Review – Issue #1 2017

Issue #4 2016

Drug Target Review – Issue #4 2016

Issue #3 2016

Drug Target Review – Issue #3 2016

Issue #2 2016

Drug Target Review – Issue #2 2016

Supplements & Special Editions

Issue #4 2019

Hit-To-Lead In-Depth Focus 2019

Issue #4 2019

Targets In-Depth Focus 2019

Issue #4 2019

Screening In-Depth Focus 2019

Issue #3 2019

Upstream Bioprocessing In-Depth Focus 2019

Issue #3 2019

Antibodies In-Depth Focus 2019

Issue #3 2019

Genomics In-Depth Focus 2019

Issue #2 2019

Screening In-Depth Focus 2019

Issue #2 2019

Imaging In-Depth Focus 2019

Issue #2 2019

Stem Cell In-Depth Focus 2019

Issue #1 2019

Lab Automation In-Depth Focus 2019

Issue #1 2019

Informatics In-Depth Focus 2019

Issue #1 2019

Assays In-Depth Focus 2019

Issue #4 2018

Application Notes supplement 2018

Issue #4 2018

Hit-to-Lead In-Depth Focus 2018

Issue #4 2018

Screening In-Depth Focus 2018